ArticleScientific reports2025
Integrated multi-sample transcriptomic analysis of COVID-19 patients against controls using a bioinformatics pipeline.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Prior coronavirus disease 2019 (COVID-19) transcriptomic studies using diverse methods for differential gene expression (DGE) profiling of specific samples yielded inconsistent results. To validate the shared molecular patterns of COVID-19 across cell, tissue, and systemic levels, we conducted a systematic rank combination meta-analysis of differentially expressed gene (DEG) profiles sourced from various sample types using a standardised bioinformatics pipeline consisting of DESeq2, RankProd, and weighted gene correlation network analysis (WGCNA). Consistently upregulated ISGs (including key hub gene IFIT2), compared with interleukins were identified in swab samples, reflecting dominant innate immune responses at the viral entry point. Blood samples revealed diverse gene functions in immune and neurological regulation, highlighting the complex interplay of systemic regulation. Significant enrichment of immunoglobulin-related and extracellular matrix genes indicates their role in the host adaptive immunity and long-term host responses in tissue samples. Novel key hub genes in tissue samples, GPD1 and CYP4A11 related to metabolic dysregulation were identified, potentially contributing to the severity of the disease. These findings portray the molecular basis of COVID-19 progression from localised innate responses to systemic effects and finally tissue-specific adaptive immunity and remodelling, providing insights that may inform diagnostic and therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.